Abstract
Forty-nine patients were treated with either 3×75 MBq 89Sr or saline as placebo. Analysis of results 1 to 3 years after therapy revealed the ineffectiveness of 89Sr to relieve pain from metastases. Unexpectedly, a higher survival rate was found after Sr application (46% vs 4% after 2 years). Covariate analysis underlines the effect of 89Sr therapy on life expectation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blake GM, Zivanovic MA, McEwan AJ, Ackery DM (1986) Sr-89 therapy: Strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12: 447–454
Buchali K, Correns HJ, Schnorr D, Schuerer M, Sydow K, Lips H (1984) Therapie mit 89-Sr bei Knochenmetastasen von Prostatakarzinomen. In: Hoefer R (ed). Radioaktive Isotope in Klinik und Forschung 16. Egermann, Vienna, pp 151–157
Correns HJ, Mebel M, Buchali K, Schnorr D, Seidel C, Mitterlechner E (1979) 89-Strontium therapy of bone metastases of carcinoma of the prostatic gland. Eur J Nucl Med 4: 33–34
Correns HJ, Buchali K, Sydow K, Schuerer M, Schnorr D, Richter K (1982) Nuklearmedizinische Therapie von Metastasen des Skelettsystems. In: Schwartz D 19th Symposion Nuklearmedizin, Reinhardsbrunn, Schriftenreihe, Berlin pp 35–40
Correns HJ, Buchali K, Schnorr D, Lips H, Sydow K, Schuerer M, Johannsen B (1986) On the efficacy of Strontium-89 therapy. Preliminary evaluation of a double-blind study. In: Winkler C (ed) Nuclear medicine in clinical oncology. Springer, Berlin Heidelberg New York Tokyo pp 345–347
Cox DR (1972) Regression models and life tables. J R Statist Soc B 34: 187–220
Firusian N, Mellin P, Schmidt CG (1976) Results of 89 Strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urology 116: 764
Firusian N (1979) Radionuklidbehandlung von Skelettmetastasen. Nuklearmediziner 4: 314–327
Kaul A, Oeff K, Roedler HD, Vogelsang T (1973) Die Strahlenbelastung von Patienten bei der nuklearmedizinischen Anwendung offener radioaktiver Stoffe. Informationsdienst Nuclearmedizin Berlin
Kutzner J, Grimm W, Hahn K (1977) Interne Strahlentherapie mit Strontium 89 bei metastasenbedingten Schmerzzustaenden. Muench Med Wochenschr 119: 1251
Kutzner J, Grimm W, Brod KH, Roesler A (1982) Die Yttrium-90 Therapie von Knochenmetastasen. Dtsch Med Wochenschr 107: 1360–1361
Langhammer H, Sintermann R, Hoer G, Pabst HW (1978) Serial bone scintigraphy for assessing the effectiveness of treatment of osseous metastases from prostatic cancer. J Nucl Med 17: 87–91
Levenson RM, Sauerbrunn BJL, Bates HR, Newman RD, Eddy JL, Ihde DC (1983) Comparative value of bone scintigraphy and radiography in monitoring tumor response in systematically treated prostatic carcinoma. Radiology 146: 513–518
Schmid L, Langhammer H, Braun J, Oberdorfer M, Steuer G, Herz R, Pabst HW (1982) Skelettszintigraphische und radiologische Befunde bei 403 Prostatakarzinompatienten in Primaerdiagnostik, Verlaufs- und Therapiekontrolle. In: Hoefer R (ed) Radioaktive Isotope in Klinik und Forschung 15. Egermann, Vienna pp 349–360
Silberstein EB, Williams C (1985) Strontium-89 therapy for the pain of osseous metastases. J Nucl Med 26: 345–348
Snyder WS, Ford MR, Warner GG, Watson SB (1975) MIRD pamphlet No. 11. Soc Nucl Med
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Buchali, K., Correns, HJ., Schuerer, M. et al. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14, 349–351 (1988). https://doi.org/10.1007/BF00254382
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254382